Vanguard Group
FDMT icon

Vanguard Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Vanguard Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$23.2M Buy
3,093,527
+518,405
+20% +$5.26M ﹤0.01% 2549
2025
Q3 		$22.4M Sell
2,575,122
-161,549
-6% -$966K ﹤0.01% 2566
2025
Q2 		$10.2M Sell
2,736,671
-20,819
-0.8% -$73.2K ﹤0.01% 2892
2025
Q1 		$8.91M Sell
2,757,490
-103,018
-4% -$485K ﹤0.01% 2907
2024
Q4 		$15.9M Buy
2,860,508
+92,791
+3% +$728K ﹤0.01% 2694
2024
Q3 		$29.9M Buy
2,767,717
+239,537
+9% +$3.98M ﹤0.01% 2402
2024
Q2 		$53.1M Buy
2,528,180
+188,237
+8% +$4.72M ﹤0.01% 2121
2024
Q1 		$74.6M Buy
2,339,943
+473,094
+25% +$12.1M ﹤0.01% 2006
2023
Q4 		$37.8M Sell
1,866,849
-35,618
-2% -$469K ﹤0.01% 2304
2023
Q3 		$24.2M Sell
1,902,467
-70,635
-4% -$1.18M ﹤0.01% 2472
2023
Q2 		$35.7M Buy
1,973,102
+427,218
+28% +$7.87M ﹤0.01% 2345
2023
Q1 		$26.6M Buy
1,545,884
+273,674
+22% +$5.32M ﹤0.01% 2461
2022
Q4 		$28.3M Sell
1,272,210
-48,152
-4% -$744K ﹤0.01% 2468
2022
Q3 		$10.6M Sell
1,320,362
-1,787
-0.1% -$16.2K ﹤0.01% 2933
2022
Q2 		$9.23M Buy
1,322,149
+31,208
+2% +$303K ﹤0.01% 3038
2022
Q1 		$19.5M Buy
1,290,941
+7,858
+0.6% +$123K ﹤0.01% 2790
2021
Q4 		$28.2M Buy
1,283,083
+337,106
+36% +$8.26M ﹤0.01% 2662
2021
Q3 		$25.5M Buy
945,977
+475,701
+101% +$13.6M ﹤0.01% 2714
2021
Q2 		$11.3M Buy
470,276
+33,014
+8% +$1.01M ﹤0.01% 3136
2021
Q1 		$19M Buy
437,262
+427,262
+4,273% +$18.9M ﹤0.01% 2809
2020
Q4 		$414K Buy
+10,000
New +$413K ﹤0.01% 3993

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group's FDMT Position: Q4 2025 in Review

Vanguard Group increased its 4D Molecular Therapeutics (FDMT) stake by 20% in Q4 2025, buying an estimated $5.26M and bringing the position to 3,093,527 shares worth $23.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Vanguard Group first reported a position in FDMT in Q4 2020 and has held it in 21 quarters since. The position peaked at $74.6M in Q1 2024. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Vanguard Group held 3,093,527 shares of 4D Molecular Therapeutics worth $23.2M as of Q4 2025.
  • Vanguard Group bought 518,405 4D Molecular Therapeutics shares in Q4 2025, an estimated $5.26M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2549 holding.
  • Vanguard Group first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's 4D Molecular Therapeutics position peaked at $74.6M in Q1 2024.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.